Efficacy of nimotuzumab (hR3) conjugated with ¹³¹I or ⁹⁰Y in laryngeal carcinoma xenograft mouse model

References

• Andreas OS, Franz B, Marek K. 2004. 131I-Rituximab: relationship between immunoreactivity and specific activity. J Nucl Med. 45:1784–1790.
   PubMed Web of Science ®Google Scholar
• Andreas PK, Linda DP, Gabriel JM, Amadeo JP, Stinnett JD. 1978. Growth patterns and metastatic behavior of human tumors growing in athymic mice. Cancer Research. 38:3186–3190.
   PubMed Web of Science ®Google Scholar
• Barta P, Laznickova A, Laznicek M, Vera DRB, Beran M. 2013. Preclinical evaluation of radiolabelled nimotuzumab, a promising monoclonal antibody targeting the epidermal growth factor receptor. J Labelled Comp Radiopharm. 56(5):280–288.
   PubMed Web of Science ®Google Scholar
• Brechbiel MW. 2008. Bifunctional chelates for metal nuclides. J Nucl Med Mol Imaging. 52(2):166–173.
   PubMed Web of Science ®Google Scholar
• Dietrich A, Andreeff M, Koi L, Kotzerke J, Baumann M, Krause M, Löck S, Sihver W, Freudenberg R, Hering S, Pietzsch HJ, et al. 2020. Radiotherapy enhances uptake and efficacy of 90Y-cetuximab: a preclinical trial. Radiother Oncol. 155:285–292.
   PubMed Web of Science ®Google Scholar
• Dongli Y, Yong S, Yemei T, Hongyu Y, Yujia G, Shuxin W, Binquan W, Changming A, Yongyan W, Wei G. 2019. Effect of HPV infection on the occurrence and development of laryngeal cancer: a review. J Cancer. 10(19):4455–4462.
   PubMed Web of Science ®Google Scholar
• Fogh J, Giovanella BC. 1982. The nude mouse in experimental and clinical research. New York: Academic Press.
   Google Scholar
• Giselle SM, Anamary BY. 2014. Nimotuzumab, effective immunotherapy for the treatment of malignant epithelial tumors. Bio Apli. 31(2):159–167.
   Google Scholar
• Gopal BS. 2012. Fundamentals of nuclear pharmacy. Philadelphia: Springer.
   Google Scholar
• Hnatowich DJ, Virzi F, Doherty PW. 1985. DTPA-coupled antibodies labeled with Yttrium-90. J Nucl Med. 26(5):503–509.
   PubMed Web of Science ®Google Scholar
• Irina V, Asa LS, Orjan L, Urban H, Olof E, Eva W, Jorgen C, Mats B, Bengt L, Vladimir T. 2005. Preparation and evaluation of 68Ga-DOTA-hEGF for visualization of EGFR expression in malignant tumor. J Nucl Med. 46(11):1881–1888.
   PubMed Web of Science ®Google Scholar
• Kaplon H, Muralidharan M, Schneider Z, Reichert JM. 2020. Antibodies to watch in 2020. MAbs. 12(1):1703531.
   PubMed Web of Science ®Google Scholar
• Konishi S, Hamacher K, Vallabhajosula S, Kothari PA, Bastidas D, Bander N, Goldsmith S. 2004. Determination of immunoreactive fraction of radiolabeled monoclonal antibodies: what is an appropriate method? Cancer Biother Radiopharm. 19:708.
   Web of Science ®Google Scholar
• Larson SM, Carrasquillo JA, Cheung NKV, Press O. 2015. Radioimmunotherapy of human tumours. Nat Rev Cancer. 15(6):347–360.
   PubMed Web of Science ®Google Scholar
• Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn PA. 1984. Determination of the immunoreactive fraction of radiolabeled monoclonal antibody by linear extrapolation to binding at infinite antigen excess. J Immunol Methods. 72(1):77–89.
   PubMed Web of Science ®Google Scholar
• Liu Z, Ma T, Liu H, Jin Z, Sun X, Zhao H, Shi J, Jia B, Li F, Wang F. 2014. 177Lu-labeled antibodies for EGFR-targeted SPECT/CT imaging and radioimmunotherapy in a preclinical head and neck carcinoma model. Mol Pharm. 11(3):800–807.
   PubMed Web of Science ®Google Scholar
• Meares CF, McCall MJ, Reardan DT, Goodwin DA, Diamanti CI, Tigue MM. 1984. Conjugation of antibodies with bifunctional chelating agents: isothiocyanate an bromoacetamide reagents, methods of analysis, and subsequent addition of metal ions. Anal Biochem. 142(1):68–78.
   PubMed Web of Science ®Google Scholar
• Mythili K, Grace S, Haladhar DS, Swamirao NS, Ashutosh D, Meera V. 2015. 131I-Nimotuzumab A potential radioimmunotherapeutic agent in treatment of tumors expressing EGFR. Appl Rad and Isotop. 102:98–102.
   PubMed Web of Science ®Google Scholar
• Ning-Yi M, Xu-Wei C, Xiao-Long F, Yuan L, Xiao-Yan Z, Xiang-Hua W, Xi-Chun H, Min F, Jia-Qing X, Ya-Wei Z, et al. 2014. Safety and efficacy of nimotuzumab in combination with radiotherapy for patients with squamous cell carcinoma of the esophagus. Int J Clin Oncol. 9(2):297–302.
   Google Scholar
• Qiang Z, Aimin L, Xiao Y, Rongcheng L. 2009. Biodistribution and anti-tumor activities of the 131I-labeled Rituximab in Nude Mice Bearing Human Burkitt’s lymphoma. Clin Oncol Cancer Res. 6(4):256–262.
   Google Scholar
• Reulen HJ, Molina ES, Reinhard Zeidler R, Gildehaus FJ, Böning G, Gosewisch A, Stummer W. 2019. Intracavitary radioimmunotherapy of high-grade gliomas: present status and future developments. Acta Neurochir. 161(6):1109–1124.
   PubMed Web of Science ®Google Scholar
• Riccardo N, Gabriele M, Camilla M, Giuseppe L. 2020. Updates on larynx cancer epidemiology. Chin J Cancer Res. 32(1):18–25.
   PubMed Web of Science ®Google Scholar
• Sai-Xi B, Ruo-Rong Z, Wang-Hua C, Hong-Min D, Gang W, Xiao-Kai L, Wenling W. 2020. Clinical efficacy and safety of nimotuzumab plus chemotherapy in patients with advanced colorectal cancer: a retrospective analysis. J Int Med Res. 48(1):1–11.
   Web of Science ®Google Scholar
• Seyedin SN, Mallak N, Mott S, Menda Y, Graham M, Anderson CM. 2017. The role of 3 month PET-CT After definitive radiation for laryngeal carcinoma. Int J Rad Oncol Biol Phys. 99(2):E371.
   Google Scholar
• Sharkey RM, Goldenberg DM. 2011. Cancer radioimmunotherapy. Immunoth. 3(3):349–370.
   PubMed Web of Science ®Google Scholar
• Shiwen Z, Yunlong L, Xiaoguang H, Shouan D, Shouan H, Xiaojiang L, Yuxiao L, Congguo J, Yingying Z, Yuanling W. 2014. Photothermolysis mediated by gold nanorods modified with EGFR monoclonal antibody induces Hep-2 cells apoptosis in vitro and in vivo. Int J Nanomed. 9:1931–1946.
   PubMed Web of Science ®Google Scholar
• Shuping X, Mayra RS, Xianhong B, Binghe X. 2016. Treatment outcome of nimotuzumab plus chemotherapy in advanced cancer patients: a single institute experience. Oncotarget. 7(22):33391–33407.
   PubMedGoogle Scholar
• Sosabowski JK, Mather SJ. 2006. Conjugation of DOTA-like chelating agents to peptides and radiolabeling with trivalent metallic isotopes. Nat Protoc. 1(2):972–976.
   PubMed Web of Science ®Google Scholar
• Tijink BM, Neri D, Leemans CR, Budde M, Dinkelborg LM, Walsum MS, Zardi L, Dongen G. 2006. Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature. J of Nucl Med. 47(7):1127–1135.
   PubMed Web of Science ®Google Scholar
• Vera DRB, Eigner S, Beran M, Henke KE, Laznickova A, Laznicek M, Melichar F, Chinol M. 2011. Preclinical evaluation of (177)lu-nimotuzumab: a potential tool for radioimmunotherapy of epidermal growth factor receptor-overexpressing tumors. Cancer Biother Radiopharm. 26(3):287–297.
   PubMed Web of Science ®Google Scholar
• Vera DRB, Eigner S, Henke KE, Melichar F, Beran M. 2011. Study of biological behaviour of the DOTA-Nimotuzumab conjugate labelled with 177Lu or 90Y in EGFR-rich cell lines and their cancer models in athymic mice. J Nucl Med. 52(1):1586.
   Google Scholar
• Yukie Y, Hiroki M, Mitsuyoshi Y, Yoko O, Ming-Rong Z, Kotaro N, Aya S, Atsushi BT, Tatsuya H. 2019. 64Cu-intraperitoneal radioimmunotherapy: a novel approach for adjuvant treatment in a clinically relevant preclinical model of pancreatic cancer. J Nucl Med. 60(10):1437–1443.
   PubMed Web of Science ®Google Scholar
• Zaheer J, Kim H, Lee YJ, Kim JS, Lim SM. 2019. Combination radioimmunotherapy strategies for solid tumors. Int J Mol Sci. 20(22):5579.
   Web of Science ®Google Scholar
• Zhanzhan L, Yanyan L, Shipeng Y, Jun F, Qin Z, Xinqiong H, Liangfang S. 2017. Nimotuzumab combined with concurrent chemoradiotherapy benefits patients with advanced nasopharyngeal carcinoma. Onco Targets Ther. 10:5445–5458.
   PubMed Web of Science ®Google Scholar